Log In
Print
BCIQ
Print
Print this Print this
 

Axitinib-MPP

  Manage Alerts
Collapse Summary General Information
Company Kala Pharmaceuticals Inc.
DescriptionAxitinib, an inhibitor of VEGF receptors 1, 2 and 3, formulated with mucosal penetrating particle (MPP) technology
Molecular Target Vascular endothelial growth factor (VEGF) receptor 1 (FLT1) (VEGFR-1) ; Vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) (VEGFR-2)
Mechanism of ActionVascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) kinase inhibitor; Vascular endothelial growth factor (VEGF) receptor 1 (Flt-1) kinase inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard IndicationAge-related macular degeneration (AMD)
Indication DetailsTreat wet age-related macular degeneration (AMD)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today